Research progress of hidden hearing loss in occupational health surveillance / 中华劳动卫生职业病杂志

According to the research on the pathogenesis of the hidden hearing loss in recent years, the occurrence of the hidden hearing loss is earlier than the permanent hearing threshold shift. This paper reviews the risk factors of hidden hearing loss, the pathogenesis of noise-induced hidden hearing loss, and the detection methods of hidden hearing loss. To explore the significance of hidden hearing loss in occupational health surveillance, and to provide reference for hearing protection of workers exposed to noise and hearing loss early in the future.

The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie's Disease in the United States

PURPOSE: We evaluated the impact of collagenase clostridium histolyticum (CCH) on rates of diagnosis, treatment, and corporal rupture in Peyronie's disease (PD). We examined the impact of CCH on cost of PD treatment. MATERIALS AND METHODS: We extracted data on PD diagnosis (ICD-9 607.95 and ICD-10 N48.6), corporal rupture (ICD-9 959.13 and ICD-10 S39.840A), CCH use (J0775), penile injections (CPT 54200), and corporal rupture repair from 2008 to 2016 in men over 40 years old using the Clinformatics® Data Mart Database (3.7 to 4.9 million males). We analyzed for prevalence of PD, rates of PD treatments, cost associated with treatment, and rates of corporal rupture and repair by year. RESULTS: The prevalence of PD was 0.29% in 2013 and did not increase after CCH entered the market in 2014. An average of 2.52% of men with PD received treatment before CCH, compared with 3.75% after (p<0.0001). Penile injection rates increased (1.34% vs. 2.61%, p<0.0001), while rates of surgical treatments decreased between these periods. There was no change in rate of corporal rupture in men with PD before (0.024%) and after (0.024%) CCH. Overall, only 20.0% of corporal ruptures were repaired. After CCH entered practice, a significant increase in cost occurred (p=0.013). CONCLUSIONS: The prevalence of men with PD did not change after CCH. However, more men with PD received treatment due to an increase in penile injections. The cost of treating PD increased after CCH became available. The overall prevalence of corporal rupture did not change after CCH entered the market.

Comparison of six irradiation techniques for delivering hypofractionated whole-breast radiotherapy with a simultaneous integrated boost after breast-conserving surgery

Background: to compare the following techniques for hypofractionated whole-breast irradiation [WBI] with simultaneous integrated boost [SIB] after breast-conserving surgery [BCS]: three-dimensional conformal radiation therapy plus electron boost [3DCRT-EB], intensity-modulated radiation therapy [IMRT] plus EB [IMRT-EB], field-in-field IMRT plus EB [FIF-IMRT-EB], FIF-IMRT plus IMRT boost [FIF-IMRT-IB], IMRT plus IMRT boost [IMRT-IB], and volumetric-modulated arc therapy [VMAT] plus VMAT boost [VMAT-VB]

Materials and Methods: twenty patients with left breast cancer were enrolled. The prescribed dose was 40.05 Gy in 15 fractions to the whole breast and an SIB to the tumor bed of 3.2 Gy/fraction [total, 48 Gy]. Target-volume coverage, dose-conformity index, homogeneity index [HI], doses to organs at risk [OAR], and costs were compared

Results: FIF-IMRT-EB performed the best, while FIF-IMRT-IB, IMRT-IB, and VMAT-VB performed the worst. The mean dose to the planning target volume for breast evaluation [PTV Eval-breast] was significantly lower for IMRT-EB and FIF-IMRT-EB than for the other plans. For both PTV Eval-breast and PTV Eval-boost, VMAT-VB had the lowest target-volume coverage for 95% of the prescription dose and the highest target-volume coverage for >105% of the prescription dose. Among the six plans, VMAT-VB had the best HI for PTV Eval-boost and the highest doses to all OAR, except the coronary artery. Plans with EBs had lower mean doses for the contralateral lung and contralateral breast than plans with IMRT boosts. FIF-IMRT-EB had a low cost; plans with IMRT boosts had the highest costs

Conclusion: FIF-IMRT-EB may be the most suitable irradiation technique for hypofractionated WBI with SIB after BCS

Relationship between serum aminotransferase levels and metabolic disorders in northern China

Increasing evidence suggests an association between ele-vated serum aminotransferase levels and metabolic disorders [metabolic syndrome, hyperlipemia and diabetes mellitus]. However, the significance of relatively low levels of aminotransferases in relation to metabolic disorders has not been fully investigated in the general population. We inves-tigated the association between serum amiontransferase levels and metabolic disorders using data from a survey in Jilin province, China. In 2007, a survey was conducted throughout Jilin, China, covering both urban and rural areas. A total of 3835 people, 18 to 79 years old including 1761 men and 2074 women, underwent real-time ultrasonography, blood tests including aspartate aminotransferase and alanine aminotransferase, and had interviews with a structured questionnaire. Serum aminotransferase levels within the normal range were asso-ciated with metabolic syndrome independent of age, occupation, cultural and educational level, income, body mass index, waist circumference, smoking, and alcohol intake. Compared with the lowest level [<20 IU/L], the adjusted odds ratios for ALT levels of 20-29, 30-39, 40-49 and>50 IU/L were 1.92, 2.50, 2.97, and 3.52 in men, and 1.38, 1.54, 3.06, and 2.62 in women, respectively. Near-normal serum aminotransferase levels asso-ciated with hyperlipemia, NAFLD, DM were also found in the study. Normal to near-normal serum aminotransferase levels are associated with metabolic disorders. Serum ALT levels of 21-25 IU/L for men and 17-22 IU/L for women are suggested as cutoff levels that detect metabolic disorders affecting the liver